MedTrace Logo

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

NCT01492374 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-07-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's disease (AD) subjects, following 9 weekly intravenous (IV) infusions of BMS-241027

Conditions

Interventions

DRUG

BMS-241027

Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks

DRUG

BMS-241027

Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks

DRUG

BMS-241027

Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks

DRUG

Placebo matching BMS-241027

Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States
  • Canada
  • France
  • Germany
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492374 on ClinicalTrials.gov